growth hormone therapy (Pfizer Inc)
86
Structured Review
Pfizer Inc
growth hormone therapy
Growth Hormone Therapy, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/growth+hormone+therapy/20+2004+30+antagonist+aptamer+degeneration+endothelial+factor+growth+kda+kda+macular+peg+vascular/pm41882068-186-7-20
Average 86 stars, based on 1 article reviews
Growth Hormone Therapy, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/growth+hormone+therapy/20+2004+30+antagonist+aptamer+degeneration+endothelial+factor+growth+kda+kda+macular+peg+vascular/pm41882068-186-7-20
Average 86 stars, based on 1 article reviews
growth hormone therapy - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Hypothalamic syndrome. Article Snippet: | Hypothalamic syndrome (HS) is a rare disorder caused by diseaserelated and/or treatment-related injury to the hypothalamus, most commonly associated with rare, noncancerous parasellar masses, such as craniopharyngiomas, germ cell tumours, gliomas, cysts of Rathke’s pouch and Langerhans cell histiocytosis, as well as with genetic neurodevelopmental syndromes, such as Prader–Willi syndrome and septooptic dysplasia.. HS is characterized by intractable weight gain associated with severe morbid obesity, multiple endocrine abnormalities and memory impairment, attention deficit and reduced impulse control as well as increased risk of cardiovascular and metabolic disorders.. Currently, there is no cure for this condition but treatments for general obesity are often used in patients with HS, including surgery, medication and counselling. Article Title: Long-term effectiveness and safety of long-acting growth hormone preparation in children with growth hormone deficiency. Article Snippet: An overview of Article Title: Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment, and follow-up. Article Snippet: Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment and follow-up Agnieszka Bogusz & Hermann L. Müller To cite this article: Agnieszka Bogusz & Hermann L. Müller (2018): Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment and follow-up, Expert Review of Neurotherapeutics, DOI: 10.1080/14737175.2018.1528874 To link to this article: https://doi.org/10.1080/14737175.2018.1528874 Article Title: Safety of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: A Systematic Review and Cohort Study. Article Snippet: 47 Geffner M, Lundberg M, Koltowska-HäggströmM, Abs R, Verhelst J, Erfurth EM, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of Article Title: Final adult height in Korean children with idiopathic growth hormone deficiency after growth hormone treatment. Article Snippet: & Article Title: Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study Article Snippet: Geffner M, Lundberg M, Koltowska-Häggström M, Abs R, Verhelst J, Erfurth EM, et al: Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of Article Title: The Diagnosis and Treatment of Craniopharyngioma. Article Snippet: 63 Geffner M, Lundberg M, KoltowskaHaggstrom M, Abs R, Verhelst J, Erfurth EM, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of Article Title: Diazoxide in Children With Obesity After Hypothalamic-Pituitary Lesions: A Randomized, Placebo-Controlled Trial. Article Snippet: Geffner M, Lundberg M, Koltowska-Häggström M, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of |